Skip to main content

Atugen Will Use siRNA Tools, GeneBlocs Tech to Help Sankyo Validate Drug Targets

NEW YORK, May 17 (GenomeWeb News) - Atugen will use its siRNA technology and GeneBlocs platform to help Japanese drug maker Sankyo validate certain undisclosed therapeutic targets.

 

Atugen, based in Berlin, will use its tools, which also include delivery reagents and functional assays, to validate an undisclosed number of Sankyo targets.

This is the second collaboration between the two companies.

Financial details of the agreement were not disclosed.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.